We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




AI Tool Predicts Immunotherapy Response Using Tumor Senescence Signals

By LabMedica International staff writers
Posted on 22 Oct 2026

Patients receiving the same cancer immunotherapy can have markedly different outcomes, with some showing little or no response. More...

Identifying these patients earlier could reduce the costs of ineffective treatment and delays in alternative therapy. Differences in the tumor microenvironment, including senescent cells that suppress immune-cell activity, may help explain this variability. Building on this connection, researchers have developed an artificial intelligence method that accounts for tumor cell senescence to predict immunotherapy response.

POSTECH (Pohang University of Science and Technology; Pohang, South Korea) developed a machine-learning method that analyzes genetic information from cancer patients to predict response to immunotherapy. The technology uses a stepwise prediction framework rather than processing all genetic information at once. It first identifies tumors with a senescent microenvironment in which immune-cell activity is suppressed, then progressively stratifies patients as likely responders or nonresponders.

The approach was designed to address a key limitation in artificial intelligence-based prediction: the small number of available patient samples compared with the large volume of genetic information. According to the researchers, this imbalance can cause models to become overly tailored to training data and perform poorly in new patients. The step-by-step method was intended to reduce bias toward any single patient group and support more robust performance across diverse populations.

In experiments, the method outperformed biomarkers currently used in clinical practice for predicting treatment response across four cancer types, including skin cancer, and six patient cohorts. It also showed consistent performance compared with other existing prediction methods when validated in an independent skin cancer cohort that had not been included in model training. The study, titled “Senescence-aware filtering facilitates robust prediction of cancer immunotherapy outcomes,” was published in npj Digital Medicine.

The findings highlight the role of a senescent tumor microenvironment in predicting immunotherapy outcomes. The researchers stated that identifying whether senescent cells may interfere with immunotherapy could support more individualized treatment strategies. The work was conducted at POSTECH.

“By taking cellular senescence into account, this prediction method could help more cancer patients benefit from immunotherapy in the future. Through follow-up studies, we will continue to develop AI-based approaches for predicting treatment response that more precisely reflect the tumor microenvironment,” said Sanguk Kim, professor in the Department of Life Sciences and the Graduate School of Convergence Science and Technology at POSTECH.

Related Links
POSTECH


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Measuring six variants from one sample may improve research efficiency and support clinical trials of amyloid biology in Alzheimer’s disease and related conditions (Image Credit: Adobe Stock)

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.